论文部分内容阅读
目的 :探讨康柏西普联合玻璃体切割术治疗增生性糖尿病视网膜病变的疗效。方法 :本研究选取了100例增生性糖尿病视网膜病变,年龄27~68岁,对照组(47例)单纯给予玻璃体切割术治疗,康柏西普组(53例)采用玻璃体切除术前3~6天眼内注射康博西普治疗。通过对患者术前术后6个月最佳矫正视力(BCVA),术前,术后3个月、6个月黄斑中心凹厚度,随访6个月期间并发症情况进行记录,评价康柏西普联合玻璃体切割术治疗增生性糖尿病视网膜病变的疗效。结果 :术前两组BCVA相比,差异没有统计学意义;术后6个月,康博西普组和对照组BCVA均明显提高,且康博西普组BCVA高于对照组,与术前相比,术后3个月,6个月的黄斑中心凹厚度均明显变薄。随访6个月期间,康博西普组并发症发生率明显低于对照组。结论 :康柏西普联合玻璃体切割术治疗增生性糖尿病视网膜病变可有效改善视力,减轻黄斑水肿症状,术后并发症较少。
Objective: To investigate the therapeutic effect of Compaqeep combined vitrectomy on proliferative diabetic retinopathy. Methods: In this study, 100 cases of proliferative diabetic retinopathy were selected, ranging in age from 27 to 68 years. The control group (47 cases) was treated with vitrectomy alone. The conpatch group (53 cases) was treated with vitrectomy 3 to 6 Day intraocular injection of Compton treatment. Preoperative and postoperative best-corrected visual acuity (BCVA) at 6 months, preoperative, postoperative 3 months, 6 months foveal thickness, follow-up of 6 months complication were recorded and evaluated Compaq West Treatment of proliferative diabetic retinopathy with combined vitrectomy. Results: There was no significant difference in BCVA between the two groups before operation. The BCVA in both groups was significantly increased at 6 months after operation compared with that in the control group , 3 months after surgery, 6 months foveal thickness were significantly thinner. During the 6-month follow-up, the complication rate in the group CompBox was significantly lower than that in the control group. Conclusions: Compaqib combined with vitrectomy in the treatment of proliferative diabetic retinopathy can effectively improve vision and reduce the symptoms of macular edema, with fewer postoperative complications.